Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

Cigna’s Evernorth unit scored a deal with Eli Lilly and Novo Nordisk to make weight loss drugs more affordable for insured ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

Cigna subsidiary Evernorth Health Services will authorize prior authorizations for GLP-1 weight-loss drugs under a new ...

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

The new diabetes company will be predominantly business-to-consumer, while Medtronic’s model was more business-to-business.

Novo Nordisk is teaming up with Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.